In NSCLC, the overexpression of SUR1 (KCNJ8 or Kir6.1) promotes cell proliferation, and silencing KCNJ8 or glibenclamide treatment decreases cell and tumor growth, as well as increasing expression of the tumor suppressor Krüppel-like factor 4 (KLF4) [83]. The gene discussed is KCNJ8; the disease is neoplasm.